PT  - JOURNAL ARTICLE
AU  - TOSHIO INUI
AU  - KENTARO KUBO
AU  - DAISUKE KUCHIIKE
AU  - YOSHIHIRO UTO
AU  - TAKAHITO NISHIKATA
AU  - NORIHIRO SAKAMOTO
AU  - MARTIN METTE
TI  - Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports
DP  - 2015 Aug 01
TA  - Anticancer Research
PG  - 4545--4549
VI  - 35
IP  - 8
4099  - http://ar.iiarjournals.org/content/35/8/4545.short
4100  - http://ar.iiarjournals.org/content/35/8/4545.full
SO  - Anticancer Res2015 Aug 01; 35
AB  - Background: Gc protein-derived macrophage-activating factor (GcMAF) immunotherapy has been steadily advancing over the last two decades. Oral colostrum macrophage-activating factor (MAF) produced from bovine colostrum has shown high macrophage phagocytic activity. GcMAF-based immunotherapy has a wide application for use in treating many diseases via macrophage activation or for use as supportive therapy. Results: Three case studies demonstrate that oral colostrum MAF can be used for serious infection and chronic fatigue syndrome (CFS) without adverse effects. Conclusion: We demonstrate that colostrum MAF shows promising clinical results in patients with infectious diseases and for symptoms of fatigue, which is common in many chronic diseases.